physIQ wins DPharm Idol 2017

Originally published in Cision

PhysIQ, a Chicago-based company that provides a Personalized Physiology Analytics (PPA) and highly scalable cloud-based platform for ambulatory patient monitoring and clinical trial support, earned DPharm Idol 2017 honors at the 7th annual DPharm: Disruptive Innovations to Advance Clinical Trials conference in Boston.

Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital health. The company provides an FDA 510k-cleared data analytics platform that processes an individual's vital signs from wearable sensors to create a personalized dynamic baseline.

"Winning DPharm Idol 2017 is a fantastic development in what has been an enormously successful year for PhysIQ," said Chris Economos, Vice President of Business Development for PhysIQ. "Pharma and biotech companies are now realizing the transformational potential of continuous biosensor data, and PhysIQ is proud to be working with the biggest names in the industry to collect and analyze these data sets using its FDA-cleared machine learning analytics. We are grateful to the DPharm leadership for bringing together such an impressive event to showcase the exciting innovation happening in real-world data collection and clinical trials overall."

"PhysIQ offers a solution which has multiple applications," DPharm Idol judge Laura Galuchie said. "We liked their ability to establish a unique 'normal' for each patient by analyzing data from commercially available biosensors. Having real-time alerts for clinicians, both in and out of clinical trials, is a game-changer."

The DPharm Idol competition enables participating companies to showcase their disruptive clinical trial services or technologies. The following companies participated in this year's DPharm Idol:

• PhysIQ
• Outcome Health
• Deep 6 AI
• eClinical Solutions
• VitalTrax
• Prevail InfoWorks

"Out of the six startup companies that presented this year with transformative technologies, we applaud PhysIQ, which was selected based on their potential to bring personalized insights based on continuous patient monitoring," DPharm Idol judge Chandra Ramanathan added.

DPharm Idol contestants were evaluated by a panel of clinical trial experts. This year's DPharm Idol judges were:

• Esther Dyson, Executive Founder, Way to Wellville
• Laura Galuchie, TransCelerate Program Lead, Merck
• Christian Gossens, PhD, MBA, Global Head Early Development Workflows, pRED Informatics, Roche Pharmaceutical Research and Early Development (pRED)
• Hassan Kadhim, Business Consultant, IS BP R&DM, Boehringer Ingelheim
• Andreas Koester, MD, PhD, Vice President, Innovation, R&D Operations, Janssen
• Sarah Krüg, Executive Director/President, Cancer 101/Society of Participatory Medicine
• Jacob LaPorte, PhD, Head of Digital Development, Novartis
• Ülo Palm, MD, PhD, Senior Vice President, Drug Development Operations, Allergan
• Chandra Ramanathan, PhD, MBA, Head, East Coast Innovation Center, Bayer, US
• Jane Rhodes, PhD, Senior Director, New Initiatives, Biogen Idec
• Dan Rothman, Chief Information Officer, Roivant Sciences
• Alicia Staley, Patient Advocate

DPharm is the annual conference that promotes clinical trial disruption and innovation. DPharm hosts hundreds of R&D innovators who participate in educational sessions, interactive presentations and networking events designed to raise the bar for the next generation of clinical trials. DPharm is organized by the Conference Forum.

About The Conference Forum

The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. To find out more, please visit their website.

About PhysIQ

PhysIQ is a company dedicated to enabling proactive care delivery models through its Personalized Physiology Analytics (PPA) and highly scalable cloud-based platform. The PhysIQ FDA 510k-cleared data analytics platform is designed to process multiple vital signs from wearable sensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships this way, PhysIQ's analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health and warrant clinical attention. With applications in both healthcare delivery and clinical trial support, PhysIQ is transforming continuous physiological data into insight for providers, health systems, payers and pharmaceutical and medical device companies. For more information, please visit the PhysIQ website.